IDL Biotech AB (XSAT:IDL) ROCE % : -46.65% (As of Jun. 2021)

View and export this data going back to 2004. Start your Free Trial

What is IDL Biotech AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IDL Biotech AB's annualized ROCE % for the quarter that ended in Jun. 2021 was -46.65%.

IDL Biotech AB ROCE % Historical Data

The historical data trend for IDL Biotech AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDL Biotech AB ROCE % Chart

IDL Biotech AB Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

ROCE %

Get a 7-Day Free Trial

16.30

4.09

-15.06

-11.08

-33.45

IDL Biotech AB Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
ROCE %	Get a 7-Day Free Trial															-42.11	-36.24	-41.78	-53.49	-46.65

IDL Biotech AB ROCE % Calculation

IDL Biotech AB's annualized ROCE % for the fiscal year that ended in Dec. 2020 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2020 )		(A: Dec. 2019 )		(A: Dec. 2020 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2020 )		(A: Dec. 2019 )		(A: Dec. 2020 )
	=	-12.183	/	( ( (52.303 - 8.812)	+	(37.85 - 8.497) )	/ 2 )
	=	-12.183	/	( (43.491	+	29.353)	/ 2 )
	=	-12.183	/	36.422
	=	-33.45 %

IDL Biotech AB's ROCE % of for the quarter that ended in Jun. 2021 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2021 )		(Q: Mar. 2021 )		(Q: Jun. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2021 )		(Q: Mar. 2021 )		(Q: Jun. 2021 )
	=	-10.98	/	( ( (33.595 - 8.42)	+	(30.939 - 9.04) )	/ 2 )
	=	-10.98	/	( ( 25.175	+	21.899 )	/ 2 )
	=	-10.98	/	23.537
	=	-46.65 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2021) EBIT data.

IDL Biotech AB (XSAT:IDL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

IDL Biotech AB ROCE % Related Terms

Thank you for viewing the detailed overview of IDL Biotech AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

IDL Biotech AB (XSAT:IDL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDL Biotech AB (XSAT:IDL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Karlsbodavagen 39, Stockholm, SWE

Website

http://www.idl.se

IDL Biotech AB develops, produces and markets In Vitro Diagnostic tests for the health care sector. It offers in vitro diagnostic tests within the clinical areas of oncology and bacteriology. The company's trademark products includes TUBEX, TPS, UBC, MonoTotal and TPAcyk.

IDL Biotech AB (XSAT:IDL) Headlines

No Headlines